Biotest AG: Trimodulin does not reach the primary endpoint in the phase II trial in patients with severe COVID-19
ValueSpectrum,
DGAP-News: Biotest AG / Key word(s): Study results 13.08.2021 / 17:00 The issuer is solely responsible for the content of this…